1. Expression of integrin α v β 3 in medullary thyroid carcinoma.
- Author
-
de Vries LH, Lodewijk L, Pijnappel EW, van Diest PJ, Schepers A, Bonenkamp HJ, van Engen-van Grunsven IA, Kruijff S, van Hemel BM, Links TP, Nieveen van Dijkum EJ, van Eeden S, van Leeuwaarde RS, Valk GD, de Keizer B, Borel Rinkes IH, and Vriens MR
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Aged, Lymphatic Metastasis, Young Adult, Prognosis, Aged, 80 and over, Tissue Array Analysis, Immunohistochemistry, Adolescent, Thyroid Neoplasms pathology, Thyroid Neoplasms metabolism, Thyroid Neoplasms genetics, Thyroid Neoplasms surgery, Carcinoma, Neuroendocrine pathology, Carcinoma, Neuroendocrine genetics, Carcinoma, Neuroendocrine metabolism, Integrin alphaVbeta3 metabolism, Biomarkers, Tumor metabolism
- Abstract
Aim: Tumor markers often remain elevated after intended curative resection of medullary thyroid carcinoma (MTC). The aim of this study was to determine the expression of α
v β3 , a promising theranostics target, in MTC and its metastases. Materials & methods: Av β3 expression was analyzed in 104 patients using a tissue microarray and correlated with clinicopathological variables and survival. Results: Cytoplasmic αv β3 positivity was seen in 70 patients and was associated with lymph node metastases at time of initial surgery. Membranous positivity was considered positive in 30 patients and was associated with sporadic MTC. Conclusion: Av β3 was expressed in the cytoplasm of 67% of MTC patients. Membranous expression, which is presumably most relevant for the theranostic use of αv β3 , was seen in 29%.- Published
- 2024
- Full Text
- View/download PDF